Asset Details
Do you wish to reserve the book?
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
Do you wish to request the book?
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study “GUNMA0702”
2020
Overview
Background
Carbon ion Radiotherapy for prostate cancer is widely used, however reports are limited from single institute or short follow up. We performed a prospective observational study (GUNMA0702) to evaluate the feasibility and efficacy of carbon ion radiotherapy for localized and locally advanced prostate cancer.
Methods
Between June 2010 and August 2013, 304 patients with localized prostate cancer were treated, with a median follow-up duration of 60 months. All patients received carbon ion radiotherapy with 57.6 Gy (RBE) in 16 fractions over 4 weeks. Hormonal therapy was given according to the risk group. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 by the National Cancer Institute.
Results
The overall 5-year biochemical relapse-free rate was 92.7%, with rates of 91.7, 93.4, and 92.0% in low-risk, intermediate-risk, and high-risk patients, respectively. The 5-year local control and overall survival rates were 98.4 and 96.6%, respectively. Acute grade 3 or greater toxicity was not observed. Late grade 2 and grade 3 genitourinary and gastrointestinal toxicity rates were 9 and 0.3%, and 0.3, and 0%, respectively.
Conclusions
The present protocol of carbon ion radiotherapy for prostate cancer provided low genitourinary and gastrointestinal toxicity with good biochemical control within 5 years.
Trial registration
University Medical Information Network Clinical Trial Registry number:
UMIN000003827
.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.